Conservation and Sustainable Use of Cryptolepis sanguinolenta

Abstract

Cryptolepis sanguinolenta (Cs) is a medicinal plant, indigenous to the West Africa sub-region and has been utilized in Ghana to treat malaria for generations. Besides being used as an antimalarial treatment in Ghana, Cs has been noted as being used in the US to treat Babesia, Lyme disease (Borreliosis burgdorferi), Bartonella, among others. The plant contains several indoloquinoline alkaloids, mainly concentrated in its root system, giving the plant its antimicrobial, antihyperglycemic, and anticancer properties. However, the destructive harvesting of the entire plant, along with its root system, is not sustainable over the long term and has already resulted in a substantial decrease in wild populations, threatening its long-term potential and survivability. This book chapter will discuss its uses, conservation strategies and cultivation protocols developed for Cs to ensure a reliable supply of plant material as well as its sustainable utilization.

Increasing the planting density of Cryptolepis sanguinolenta (Lindl.) Schlt increased root biomass and cryptolepine yield

“…In addition to its use in treating malaria, C. sanguinolenta and its constituents have been found to possess antimycobacterial [ 8 ], antimicrobial [ 9 , 10 ], antihyperglycemic [ 11 ], and anticancer [ 12 ] potential. According to Opoku-Agyemang et al [ 13 ] it is used to treat diseases such as Babesia, Lyme disease ( Borreliosis burgdorferi ) and Bartonella in the United States of America. In January 2021, the Food and Drugs Authority (FDA) of Ghana approved the plant for clinical trials as a potential treatment for the Coronavirus disease (COVID-19) [ 14 ].…”